Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia

Standard

Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. / Rentzsch, Johannes; Stadtmann, Ada; Montag, Christiane; Kunte, Hagen; Plöckl, Doris; Hellweg, Rainer; Gallinat, Jürgen; Kronenberg, Golo; Jockers-Scherübl, Maria Christiane.

in: EUR ARCH PSY CLIN N, Jahrgang 266, Nr. 5, 01.08.2016, S. 409-21.

Publikationen: SCORING: Beitrag in Fachzeitschrift/ZeitungSCORING: ZeitschriftenaufsatzForschungBegutachtung

Harvard

Rentzsch, J, Stadtmann, A, Montag, C, Kunte, H, Plöckl, D, Hellweg, R, Gallinat, J, Kronenberg, G & Jockers-Scherübl, MC 2016, 'Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia', EUR ARCH PSY CLIN N, Jg. 266, Nr. 5, S. 409-21. https://doi.org/10.1007/s00406-015-0616-y

APA

Rentzsch, J., Stadtmann, A., Montag, C., Kunte, H., Plöckl, D., Hellweg, R., Gallinat, J., Kronenberg, G., & Jockers-Scherübl, M. C. (2016). Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. EUR ARCH PSY CLIN N, 266(5), 409-21. https://doi.org/10.1007/s00406-015-0616-y

Vancouver

Rentzsch J, Stadtmann A, Montag C, Kunte H, Plöckl D, Hellweg R et al. Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia. EUR ARCH PSY CLIN N. 2016 Aug 1;266(5):409-21. https://doi.org/10.1007/s00406-015-0616-y

Bibtex

@article{3036bbe779064942b43b2e3421815fd6,
title = "Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia",
abstract = "Long-term cannabis use may confer cognitive deficits and increased risk of psychosis. However, the relationship between cannabis use and schizophrenia is complex. In particular, little is known about the effects of chronic cannabis use on the attention-related electric brain response in schizophrenia. We investigated auditory novelty and oddball P300 evoked potentials in a mixed sample of first-episode and chronic schizophrenic patients and healthy controls with (SZCA, n = 20; COCA, n = 20, abstinence ≥28 days) or without (SZ, n = 20; CO, n = 20) chronic cannabis use. Duration of regular cannabis use was 8.3 ± 5.6 (SZCA) and 9.1 ± 7.1 (COCA) years. In general, schizophrenic patients showed reduced P300 amplitudes. Cannabis use was associated with both a reduced early and late left-hemispheric novelty P300. There was a significant 'diagnosis × cannabis' interaction for the left-hemispheric late novelty P300 in that cannabis use was associated with a reduced amplitude in the otherwise healthy but not in the schizophrenic group compared with their relative control groups (corrected p < 0.02; p > 0.9, respectively). The left-hemispheric late novelty P300 in the otherwise healthy cannabis group correlated inversely with amount and duration of cannabis use (r = -0.50, p = 0.024; r = -0.57, p = 0.009, respectively). Our study confirms attentional deficits with chronic cannabis use. However, cannabis use may lead to different cognitive sequelae in patients with schizophrenia and in healthy controls, possibly reflecting preexisting alterations in the endocannabinoid system in schizophrenia.",
author = "Johannes Rentzsch and Ada Stadtmann and Christiane Montag and Hagen Kunte and Doris Pl{\"o}ckl and Rainer Hellweg and J{\"u}rgen Gallinat and Golo Kronenberg and Jockers-Scher{\"u}bl, {Maria Christiane}",
year = "2016",
month = aug,
day = "1",
doi = "10.1007/s00406-015-0616-y",
language = "English",
volume = "266",
pages = "409--21",
journal = "EUR ARCH PSY CLIN N",
issn = "0940-1334",
publisher = "D. Steinkopff-Verlag",
number = "5",

}

RIS

TY - JOUR

T1 - Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia

AU - Rentzsch, Johannes

AU - Stadtmann, Ada

AU - Montag, Christiane

AU - Kunte, Hagen

AU - Plöckl, Doris

AU - Hellweg, Rainer

AU - Gallinat, Jürgen

AU - Kronenberg, Golo

AU - Jockers-Scherübl, Maria Christiane

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Long-term cannabis use may confer cognitive deficits and increased risk of psychosis. However, the relationship between cannabis use and schizophrenia is complex. In particular, little is known about the effects of chronic cannabis use on the attention-related electric brain response in schizophrenia. We investigated auditory novelty and oddball P300 evoked potentials in a mixed sample of first-episode and chronic schizophrenic patients and healthy controls with (SZCA, n = 20; COCA, n = 20, abstinence ≥28 days) or without (SZ, n = 20; CO, n = 20) chronic cannabis use. Duration of regular cannabis use was 8.3 ± 5.6 (SZCA) and 9.1 ± 7.1 (COCA) years. In general, schizophrenic patients showed reduced P300 amplitudes. Cannabis use was associated with both a reduced early and late left-hemispheric novelty P300. There was a significant 'diagnosis × cannabis' interaction for the left-hemispheric late novelty P300 in that cannabis use was associated with a reduced amplitude in the otherwise healthy but not in the schizophrenic group compared with their relative control groups (corrected p < 0.02; p > 0.9, respectively). The left-hemispheric late novelty P300 in the otherwise healthy cannabis group correlated inversely with amount and duration of cannabis use (r = -0.50, p = 0.024; r = -0.57, p = 0.009, respectively). Our study confirms attentional deficits with chronic cannabis use. However, cannabis use may lead to different cognitive sequelae in patients with schizophrenia and in healthy controls, possibly reflecting preexisting alterations in the endocannabinoid system in schizophrenia.

AB - Long-term cannabis use may confer cognitive deficits and increased risk of psychosis. However, the relationship between cannabis use and schizophrenia is complex. In particular, little is known about the effects of chronic cannabis use on the attention-related electric brain response in schizophrenia. We investigated auditory novelty and oddball P300 evoked potentials in a mixed sample of first-episode and chronic schizophrenic patients and healthy controls with (SZCA, n = 20; COCA, n = 20, abstinence ≥28 days) or without (SZ, n = 20; CO, n = 20) chronic cannabis use. Duration of regular cannabis use was 8.3 ± 5.6 (SZCA) and 9.1 ± 7.1 (COCA) years. In general, schizophrenic patients showed reduced P300 amplitudes. Cannabis use was associated with both a reduced early and late left-hemispheric novelty P300. There was a significant 'diagnosis × cannabis' interaction for the left-hemispheric late novelty P300 in that cannabis use was associated with a reduced amplitude in the otherwise healthy but not in the schizophrenic group compared with their relative control groups (corrected p < 0.02; p > 0.9, respectively). The left-hemispheric late novelty P300 in the otherwise healthy cannabis group correlated inversely with amount and duration of cannabis use (r = -0.50, p = 0.024; r = -0.57, p = 0.009, respectively). Our study confirms attentional deficits with chronic cannabis use. However, cannabis use may lead to different cognitive sequelae in patients with schizophrenia and in healthy controls, possibly reflecting preexisting alterations in the endocannabinoid system in schizophrenia.

U2 - 10.1007/s00406-015-0616-y

DO - 10.1007/s00406-015-0616-y

M3 - SCORING: Journal article

C2 - 26182894

VL - 266

SP - 409

EP - 421

JO - EUR ARCH PSY CLIN N

JF - EUR ARCH PSY CLIN N

SN - 0940-1334

IS - 5

ER -